Wall Street analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI – Get Rating) to report $410,000.00 in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $550,000.00. Infinity Pharmaceuticals posted sales […]
Medical News Forecast for December 6-12 | Physician s Weekly physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
Author Bio
A Fool since 2019, Prosper s writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances and enjoys it just as much when they return the favor. In his free time, you ll find him curling up with a good book or doing math.
What happened?
Shares of biotech company
Infinity Pharmaceuticals (NASDAQ:INFI) are soaring through the roof on Thursday following the company s release of data from a phase 2 clinical trial for one of its pipeline candidates. As of 12:03 p.m. EST, the drugmaker s stock was up by 21%, after jumping by as much as 51.4% earlier today.